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Background: There is dearth of data on the epidemiology, clinical features, and outcomes of 25	  
active tuberculosis (TB) in pregnancy.  Current studies of TB in pregnancy have shown 26	  
varied results and the relationship between TB and adverse pregnancy outcomes remains 27	  
unclear. 28	  
Objectives: We conducted a systematic review and meta-analysis to evaluate pregnancy 29	  
outcomes associated with TB. 30	  
Search strategy: Major	  databases were searched from inception until December 2015 using 31	  
terms: “TB’, ‘pregnancy’, ‘maternal morbidity’, ‘mortality’ and ‘perinatal morbidity’, 32	  
‘mortality’. There was no language or regional restrictions. 33	  
Selection criteria: We included studies that compared outcomes of women with TB, with 34	  
women without TB as controls. 35	  
Data collection and analysis: Background and outcome data were extracted.  We computed 36	  
odds ratios for maternal and perinatal complications, and pooled using a random effects 37	  
model. We assessed for heterogeneity between studies using the I2 tests and used the 38	  
Newcastle-Ottawa scale to assess the quality of the studies. 39	  
Main results: Thirteen studies, including 3384 pregnancies with active TB and 119448 40	  
without TB were eligible for inclusion. Pregnancy with active TB was associated with 41	  
increased odds of maternal morbidity (OR 2·8, 95% CI 1·7–4·6; I2=60·3%), anaemia  (OR 3·9, 42	  
95% CI 2·2–6·7; I2=29·8%), caesarean delivery (OR 2·1, 95% CI 1·2-3·8; I2=61·1%), preterm 43	  
birth (OR 1·7, 95% CI 1·2–2·4; I2=66·5%), low birth weight (OR 1·7, 95% CI 1·2–2·4; 44	  
I2=53·7%), birth asphyxia (OR 4·6, 95% CI 2·4–8·6; I2=46·3), and perinatal death (OR 4·2, 45	  
95% CI 1·5–11·8; I2=57·2%) compared to pregnant women without Tuberculosis.  46	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Conclusion: Active TB disease in pregnancy is associated with adverse maternal and fetal 47	  
outcomes. Early diagnosis of TB in the antenatal period is important to prevent significant 48	  
maternal and perinatal morbidity.  49	  
Key words: Active, tuberculosis, maternal, perinatal, pregnancy outcomes. 50	  
Tweetable abstract: Active tuberculosis in pregnancy is associated with adverse maternal 51	  
and perinatal outcomes. 52	  
Word count: 278  53	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Introduction  54	  
Tuberculosis (TB) is one of the world’s deadliest communicable diseases.(1) In 2013, an 55	  
estimated 9 million people developed active TB and 1·5 million died from the disease, 510 56	  
thousand of these were women.(1) TB is one of the leading causes of death in women of 57	  
reproductive age (15–45 years),(3) globally it is estimated that as many as 216500 pregnant 58	  
women have active TB.(2) Indirect maternal deaths now account for 28% of total maternal 59	  
deaths; 15-35% of these deaths are due to TB.(3, 4)  60	  
Although the greatest burden of TB infection is in resource-limited countries, resource-rich 61	  
countries have seen a resurgence of TB, largely as a result of an increase in migrant 62	  
populations. (5) The areas which have the highest TB burden; South-east Asia, Western pacific 63	  
and African regions, also have the highest maternal mortality rates.(1) 64	  
 65	  
Studies of active TB in pregnancy have shown varied results and the relationship between TB 66	  
and adverse pregnancy outcomes remains unclear.(6) Quantitative data synthesis can 67	  
overcome this deficiency and imprecision.  Reviews exist regarding TB in pregnancy, but 68	  
none has been conducted in a systematic manner or included meta-analysis.(7) We conducted a 69	  
systematic review to collate the evidence on maternal and perinatal outcomes of pregnancies 70	  
associated with active TB.   71	  
 72	  
Method   73	  
Study selection 74	  
Medline, Embase, Web of science and Scopus databases were searched using the subject 75	  
keywords and MeSH terms for ‘TB’, ‘pregnancy’, ‘maternal morbidity’, ‘Maternal mortality’ 76	  
and ‘perinatal morbidity’, ‘perinatal mortality’. We also searched all references of review 77	  
papers and relevant articles.  The search was not restricted by language and included all 78	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articles from inception till December 2015 (Appendix S1).  Additionally, we searched the 79	  
reference lists of the included studies for eligible papers.  Two independent reviewers (SS, 80	  
HK) identified all relevant abstracts using  pre-specified inclusion and exclusion criteria in a 81	  
two- stage process.  In the first stage, we screened the titles and abstracts of all citations for 82	  
potentially relevant papers.  In the second stage, we examined in detail the full texts of the 83	  
retrieved papers. Any discrepancies were resolved after discussion with a third reviewer (KK). 84	  
Studies were included if they had a cohort of pregnant women with TB and pregnant women 85	  
without TB as a control group and had pregnancy outcome data included.  86	  
 87	  
Quality assessment of the included studies 88	  
The Newcastle-Ottawa scale was used to assess the quality of included studies to evaluate the 89	  
risk of bias in the selection, comparability of subjects and cohorts, and of the outcome.(8) Two 90	  
independent reviewers (SS and HK) allocated stars for adherence to a pre-specified criterion. 91	  
Studies that scored four stars for selection, two stars for comparability and three stars for 92	  
ascertainment of the outcome were regarded to have a low risk of bias. Studies with two or 93	  
three stars for selection, one for comparability and two for outcome ascertainment were 94	  
considered to have a medium risk of bias. Any study with a score of one for selection or 95	  
outcome ascertainment, or zero for any of the three domains was deemed to have a high risk 96	  
of bias. 97	  
Data extraction and analysis 98	  
Using a piloted data extraction form, information on study design, setting, population 99	  
characteristics, TB diagnosis and treatment as well as maternal and perinatal outcomes were 100	  
obtained. Two independent reviewers (SS and HK) extracted data in 2×2 tables for 101	  
comparative dichotomous outcomes.  102	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Standard WHO definitions were used for the following outcomes: maternal mortality, 103	  
perinatal mortality and preterm birth.(9, 10) Maternal morbidity was defined as any health 104	  
condition attributed to and/or aggravated by pregnancy and childbirth that had a negative 105	  
impact on the woman’s wellbeing.(11) We accepted the authors’ definitions of other fetal 106	  
complications such as small for gestational age.   107	  
We calculated the odds ratios of adverse pregnancy outcomes in women with TB and women 108	  
without TB for individual studies and pooled them to obtain an overall estimate using a 109	  
random effects model, as we anticipated heterogeneity between studies. For continuous data, 110	  
we computed weighted mean difference that was pooled using a random effects model.   We 111	  
assessed for heterogeneity between studies using the I2 tests.  A rough guide to interpretation 112	  
of I2 statistics is as follows:  0% to 40%: might not be important; 30% to 60%: may represent 113	  
moderate heterogeneity, 50% to 90%: may represent substantial heterogeneity and 75% to 114	  
100%: considerable heterogeneity.  All analyses were undertaken using Stata SE.12 statistical 115	  
software.(12)  116	  
Results  117	  
Characteristics of included studies 118	  
Thirteen out of 7521 studies met the inclusion criteria (Figure 1). The studies included 3384 119	  
pregnant women with active TB and 119,448 healthy pregnant women as controls. The 120	  
diagnosis of active TB was made by a combination of clinical and radiological findings 121	  
supported by microbiological and/or histological confirmation. Of the 3384 women with 122	  
active TB, 2423 (72%) had pulmonary disease, 199 (5.8%) had extra-pulmonary disease and 123	  
three patients had both pulmonary and extra-pulmonary disease. The site of TB disease was 124	  
not stated in 22% of cases.(13) Only 7 women had HIV co-infection. One study excluded 125	  
patients with HIV.(13) Not all studies included complete data on timing of diagnosis, of 3384 126	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women with TB, timing of diagnosis was included for 1135 women. The timing of diagnosis 127	  
and treatment varied among this group, 827 (73%) patients were found to have active TB pre-128	  
conception, 127 (11%) in the 1st trimester, 135 (12%) in 2nd trimester, 46 (4%) in the third 129	  
trimester or the post-partum period. Regimens of anti tuberculosis therapy were documented 130	  
in 62 % of studies, the details of which are provided in table S1. Furthermore, in five studies 131	  
the precise proportion of patients who received treatment and the regimen received was not 132	  
recorded.(14-18) 133	  
Nearly half of the studies (6/13) were from low-income and middle-income countries. Sixty-134	  
one per cent (8/13) of the studies were published after the year 2000.  Ten studies reported on 135	  
preterm birth as an outcome, six studies reported on low birth weight, seven on perinatal 136	  
death, four on congenital anomalies, three on asphyxia and two reported on small for 137	  
gestational age and acute fetal distress.  Low Apgar score at one minute was reported only by 138	  
one study.  For maternal outcomes, five studies reported maternal death as an outcome, five 139	  
described maternal morbidity, five reported on delivery by caesarean section and three 140	  
reported on the presence of anaemia. Miscarriage and antenatal admission were reported by 141	  
one study each. Study characteristics are shown in table S1.  142	  
 143	  
Quality assessment 144	  
The quality of the studies is shown in figure 2. All of the included studies had low or medium 145	  
risk of bias for study selection, and outcome assessment. 7/13 had low risk of bias for 146	  





Maternal and perinatal outcomes 150	  
Maternal and perinatal outcomes were consistently poorer in pregnant women with active TB 151	  
infection compared to those without.  Although not significant, a trend towards more 152	  
maternal deaths in women with active TB was present (OR 4·1, 95% CI 0·65–25.2; I2=0%).  153	  
Of the women who died 50% had HIV co-infection.  Maternal morbidity was almost 3 times 154	  
greater (OR 2·8, 95% CI 1·7–4·6; I2=60.3%) in pregnant women with TB compared to the 155	  
control group.   The odds of antenatal admission were 9 times greater (OR 9·6, 95% CI; 2·3–156	  
40·6). The odds of maternal anaemia were 4 times greater in the TB group compared to 157	  
control (OR 3·85, 95% CI 2·21–6·71; I2=29·8%). Caesarean section was performed twice as 158	  
often in women with TB (OR 2·10, 95% CI 1·17–3·79; I2=61%).  The odds of miscarriage 159	  
were 9 times greater in women with TB (OR 9·06; 95% CI 4·93–16·67).  (Figure 3) 160	  
 161	  
Of the perinatal outcomes, perinatal death was 4 times more frequent in patients with TB (OR 162	  
4·2, 95% CI 1·49 –11·83; I2=57·2%), preterm birth was 1·6 times greater, (OR 1·7, 95% CI 163	  
1·2–2·4; I2=66·5%), low birth weight was 1·7 times greater (OR 1·7, 95% CI 1·2 –2·4; 164	  
I2=83·1%). Low Apgar score at one minute was 5 times greater (OR 5·71, 95% CI 1·4–22·6) 165	  
and acute fetal distress was 2·3 times greater (OR 2·34, 95% CI 1·2–4·5; I2=0%) compared to 166	  
babies born in the control group. (Figure 4)  There was a non-significant difference for the 167	  
risks of small for gestational age (OR 1·7, 95% CI 0·76–4·2; I2=83%), and congenital 168	  
anomalies (OR3·4, 95% CI 0.71–16.7; I2=73%).   169	  
Babies born to mothers with TB had a lower mean birth weight (weighted mean difference -170	  
278.25g. (95% CI -367.21– -0·189.29; I2=40.7%) and were born at an earlier gestation 171	  
(weighted mean difference -0·84 weeks (95% CI -1.22– -0·47), I2=35.6%) compared to those 172	  




Outcomes by site of disease 175	  
With regards to site of TB disease, four studies presented data exclusively on pulmonary 176	  
disease(16-19)and two studies on extra-pulmonary TB.(15, 20) There was a trend towards worse 177	  
maternal outcomes with extra-pulmonary TB (Table S2). Additionally in one study(20) among 178	  
women with extra-pulmonary TB, those that had lymph node disease had no adverse 179	  
outcomes, but TB at other extra-pulmonary sites did adversely affect pregnancy.  180	  
 181	  
Outcomes by timing of diagnosis 182	  
Breakdown of outcomes by timing of diagnosis and treatment showed better outcomes when 183	  
treatment was initiated in first trimester in comparison to second and third trimester.  In one 184	  
study none (0/9) of the pregnant women who were treated in the first trimester had preterm 185	  
birth compared to 33% (4/12) who initiated treatment in second and third trimester.(21) For 186	  
those who were treated in first trimester, there were no cases (0/9) of perinatal death 187	  
compared to 23% (3/13) in those treated in the second and third trimesters.  In mothers who 188	  
were treated in the first trimester 28% (2/7) developed complications compared to 60% (6/10) 189	  
in those who were treated in the second and third trimester. Another study (22) also found that 190	  
no woman (0/23) who was treated in first trimester had a baby with low birth weight 191	  







Main findings 197	  
Our systematic review highlights that maternal and perinatal outcomes were consistently 198	  
poorer in pregnant women with active TB compared to those without. There was an increased 199	  
odds of maternal morbidity, anaemia, perinatal death, preterm birth, low birth weight and 200	  
fetal distress in pregnant women with active TB.   The outcomes appear worse when anti 201	  
tuberculous treatment (ATT) was started late.  202	  
 203	  
Strengths and limitations 204	  
To our knowledge, this is the first review that systematically evaluates the risk of active TB 205	  
in pregnancy, and was carried out in a stringent manner to reduce bias.   The strength of this 206	  
review is that it provides the current best evidence summary exploring studies’ characteristics, 207	  
quality and results, which leads to a deeper insight into the topic than that afforded by 208	  
individual studies.  209	  
Although the studies included a significant number of patients with active TB, not all studies 210	  
had data available for all maternal and perinatal outcomes. Furthermore although most 211	  
studies included information on site of disease, and timing of diagnosis, this was not linked to 212	  
maternal and perinatal outcomes, making subgroup analysis difficult. Between study 213	  
heterogeneity was moderate for a number of outcomes, and this should be taken to account 214	  
when interpreting the results. Studies used different treatment regimens, which may be an 215	  
unexplored source of heterogeneity.   43% of studies had a medium risk of bias, however 216	  
after excluding these studies in a sensitivity analysis, there was still significantly poorer 217	  





Clinical diagnosis of active TB in pregnant women can be difficult and there is often a delay 221	  
in diagnosis due to the non-specific symptoms related to the physiological response to 222	  
pregnancy(23). In low and middle income countries, where TB carries the greatest burden, 223	  
pregnancy maybe one of the few opportunities to assess a woman’s health. Pregnancy is 224	  
therefore an ideal opportunity to screen for active TB disease, this is in line with WHO 225	  
recommendation of integrating TB screening and investigation into reproductive health 226	  
services including antenatal and postnatal care in HIV and TB prevalent regions.(4) Different 227	  
tests have been used in antenatal care such as symptom check, routine sputum examination 228	  
by smear (24, 25), and the Xpert® MTB/RIF assay(26, 27). However, there are no guidelines for 229	  
routine screening for active TB in pregnancy.  The tuberculin skin test and the interferon 230	  
gamma release assays have been used to screen for latent TB infection (LTBI) in pregnancy, 231	  
however only HIV infected pregnant women are prioritized for LTBI screening according to 232	  
WHO guidelines.(28)  233	  
The effects of active TB on pregnancy may be influenced by many factors, including the 234	  
extent of the disease, the presence of pulmonary TB vs extra-pulmonary, other comorbidities 235	  
and the timing of diagnosis and initiation of treatment. Over 50% of maternal mortality 236	  
occurring in mothers with TB in pregnancy is thought to be due to co-infection with HIV.(29) 237	  
Unfortunately there were not many women with documented HIV infection included in our 238	  
review, this may be explained by the fact that a few large studies were conducted before HIV 239	  
testing was done routinely.  It is well known that women with TB / HIV co-infection have 240	  
poorer outcomes.(30) Although studies on HIV/ TB co-infection have been conducted in 241	  




Future large prospective studies are needed to further examine the effect of active TB on 244	  
maternal and fetal outcomes in pregnancy especially from regions with high burden of 245	  
disease such as Sub-Saharan Africa and Indian Subcontinent.  Risk factors affecting maternal 246	  
and perinatal outcomes such as HIV co-infection, site of disease (pulmonary or extra-247	  
pulmonary), timing, type and length of ATT need to be further studied.  Congenital TB is an 248	  
important outcome causing significant morbidity to the infant, unfortunately this was not 249	  
reported by any of the included studies.  Future studies should collect data on this important 250	  
outcome.    251	  
Conclusion  252	  
Active TB disease in pregnancy is associated with adverse pregnancy outcomes. Early 253	  
diagnosis of TB in the antenatal period is important to prevent significant maternal and 254	  
perinatal morbidity and mortality.   255	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Figure 1: Study selection process for the systematic review on pregnancy outcomes in 
women with Tuberculosis (TB) and those without TB   
Figure 2: Quality assessment using the Newcastle-Ottawa Scale of studies included in the 
systematic review on pregnancy outcomes in women with Tuberculosis  
Figure 3: Maternal outcomes in women with Tuberculosis (TB) compared to those without 
TB.  




Appendix S1: Search Strategy for systematic review on pregnancy outcomes in Tuberculosis 
Table S1: Characteristics of studies included in a systematic review on pregnancy outcomes 
in Tuberculosis 
Figure S1: Weighted mean difference for perinatal outcomes (gestation age & birth weight) 
in women with Tuberculosis compared to those without TB.  
Table S2: Outcomes of pregnancy in women with Tuberculosis by site of disease. 
 
 
 
 
 
